HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

S Yamagishi Selected Research

Nifedipine (Adalat)

11/2007Bay w 9798, a dihydropyridine structurally related to nifedipine with no calcium channel-blocking properties, inhibits tumour necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
1/2007Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells.
1/2007Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker.
1/2007Revival of nifedipine, a dihydropyridine-based calcium blocker.
1/2005Atheroprotective properties of nifedipine.
1/2005Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
1/2004Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation.
1/2004Nifedipine inhibits tumor necrosis factor-alpha-induced leukocyte adhesion to endothelial cells by suppressing vascular cell adhesion molecule-1 (VCAM-1) expression.
1/2003Nifedipine inhibits apoptotic cell death of cultured endothelial cells induced by tumor necrosis factor-alpha.
1/2003Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


S Yamagishi Research Topics

Disease

19Atherosclerosis
08/2011 - 01/2003
18Insulin Resistance
05/2015 - 01/2005
14Diabetic Nephropathies (Diabetic Nephropathy)
09/2016 - 01/2001
14Diabetic Retinopathy (Retinopathy, Diabetic)
01/2006 - 01/2002
10Hypertension (High Blood Pressure)
11/2007 - 01/2005
9Hyperglycemia
08/2015 - 01/2004
9Inflammation (Inflammations)
11/2008 - 07/2000
9Diabetic Angiopathies (Diabetic Angiopathy)
01/2007 - 08/2000
8Cardiovascular Diseases (Cardiovascular Disease)
08/2008 - 01/2004
7Type 2 Diabetes Mellitus (MODY)
11/2008 - 01/2002
7Metabolic Syndrome (Dysmetabolic Syndrome X)
12/2007 - 01/2005
7Diabetes Mellitus
01/2007 - 01/2005
6Neoplasm Metastasis (Metastasis)
08/2008 - 03/2003
5Melanoma (Melanoma, Malignant)
05/2013 - 01/2004
5Alzheimer Disease (Alzheimer's Disease)
01/2007 - 01/2004
4Body Weight (Weight, Body)
04/2015 - 01/2002
4Neoplasms (Cancer)
05/2013 - 03/2003
4Hepatocellular Carcinoma (Hepatoma)
09/2008 - 12/2006
4Glucose Intolerance
09/2006 - 01/2005
3Vascular System Injuries
09/2011 - 12/2006
3Obesity
03/2011 - 01/2005
3Coronary Artery Disease (Coronary Atherosclerosis)
01/2011 - 01/2006
3Liver Diseases (Liver Disease)
01/2009 - 01/2005
3Neurodegenerative Diseases (Neurodegenerative Disease)
01/2007 - 01/2004
3Dehydration (Water Stress)
01/2007 - 01/2004
2Albuminuria
08/2015 - 07/2001
2Dyslipidemias (Dyslipidemia)
05/2015 - 01/2005
2Infections
01/2015 - 01/2009
2Pancreatic Neoplasms (Pancreatic Cancer)
05/2013 - 01/2005
2Uveitis
01/2008 - 11/2007
2Necrosis
11/2007 - 11/2006
2Allergic Rhinitis
03/2007 - 09/2000
2Fatty Liver
01/2006 - 01/2005
2Osteoporosis
01/2006 - 01/2005
2Hypercholesterolemia
01/2006 - 01/2006
2Myocardial Infarction
01/2005 - 01/2005
2Disease Progression
01/2005 - 01/2005
1Corneal Neovascularization
09/2016

Drug/Important Bio-Agent (IBA)

43Advanced Glycation End ProductsIBA
03/2016 - 08/2000
13pigment epithelium-derived factorIBA
01/2011 - 01/2002
10Nifedipine (Adalat)FDA LinkGeneric
11/2007 - 01/2003
9Proteins (Proteins, Gene)FDA Link
09/2016 - 01/2004
9Insulin (Novolin)FDA Link
04/2015 - 01/2002
91,4-dihydropyridine (dihydropyridine)IBA
11/2007 - 01/2003
8Glucose (Dextrose)FDA LinkGeneric
03/2016 - 01/2002
8Telmisartan (Micardis)FDA Link
03/2011 - 01/2005
8CalciumIBA
11/2007 - 01/2003
7Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2009 - 01/2004
7Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
01/2008 - 02/2003
6Biomarkers (Surrogate Marker)IBA
05/2015 - 01/2004
6Retinaldehyde (Retinal)IBA
11/2007 - 01/2002
6Reactive Oxygen Species (Oxygen Radicals)IBA
11/2007 - 01/2003
5CytokinesIBA
06/2007 - 01/2004
5Angiotensin IIIBA
12/2006 - 01/2003
5CarbohydratesIBA
09/2006 - 01/2005
4Atorvastatin (Lipitor)FDA Link
05/2015 - 12/2006
4Metformin (Glucophage)FDA LinkGeneric
05/2013 - 01/2005
4Nateglinide (Starlix)FDA LinkGeneric
03/2011 - 12/2007
4Triglycerides (Triacylglycerol)IBA
01/2009 - 01/2005
4GlyceraldehydeIBA
09/2008 - 01/2002
4PPAR gammaIBA
03/2008 - 01/2005
4azelnidipineIBA
11/2006 - 01/2005
4Glycoside Hydrolase InhibitorsIBA
09/2006 - 01/2005
4AcarboseFDA LinkGeneric
09/2006 - 01/2005
4PyridoxamineIBA
01/2006 - 01/2005
3FructoseIBA
04/2015 - 01/2005
3LipidsIBA
11/2008 - 01/2006
3Angiotensin II Type 1 Receptor BlockersIBA
03/2008 - 01/2005
3N,N-dimethylarginine (asymmetric dimethylarginine)IBA
01/2008 - 01/2007
3Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
06/2007 - 01/2004
3Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2006 - 01/2006
2AdipokinesIBA
05/2015 - 01/2006
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2013 - 01/2002
2CholesterolIBA
08/2011 - 01/2006
2Receptor for Advanced Glycation End ProductsIBA
03/2011 - 03/2011
2Nonesterified Fatty Acids (NEFA)IBA
09/2010 - 01/2005
2Glycoproteins (Glycoprotein)IBA
03/2009 - 01/2005
2Serine (L-Serine)FDA Link
09/2008 - 03/2008
2Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
11/2007 - 09/2000
2Anti-Inflammatory Agents (Anti-Inflammatories)IBA
07/2007 - 12/2006
2polyolIBA
06/2007 - 04/2003
2Protein Kinase CIBA
06/2007 - 01/2004
2Calcium Channel Blockers (Blockers, Calcium Channel)IBA
01/2007 - 11/2006
2C-Reactive ProteinIBA
01/2007 - 12/2006
2LDL Lipoproteins (beta Lipoproteins)IBA
01/2007 - 01/2006
2YM 529IBA
01/2006 - 01/2005
2Oxidoreductases (Dehydrogenase)IBA
01/2006 - 01/2006
2LDL CholesterolIBA
01/2006 - 01/2006
2Coenzyme A (CoA)IBA
01/2006 - 01/2006
2LigandsIBA
01/2005 - 01/2005
2MitogensIBA
01/2005 - 01/2003
2Pharmaceutical PreparationsIBA
01/2005 - 01/2005
1Peptides (Polypeptides)IBA
09/2016
1Sodium-Glucose Transporter 2 InhibitorsIBA
03/2016
18-Hydroxy-2'-DeoxyguanosineIBA
08/2015
1empagliflozinIBA
08/2015

Therapy/Procedure

8Therapeutics
03/2011 - 01/2004
2Oral Administration
09/2006 - 01/2005
2Glycemic Control
01/2005 - 01/2004
1Cautery
09/2016